Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diclofenac epolamine metered dose spray film - Virpax Pharmaceuticals

Drug Profile

Diclofenac epolamine metered dose spray film - Virpax Pharmaceuticals

Alternative Names: Diclofenac epolamine - Virpax Pharmaceuticals; DSF-100; Epoladerm; OSF-200

Latest Information Update: 21 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Virpax Pharmaceuticals
  • Developer MedPharm; Virpax Pharmaceuticals
  • Class Analgesics; Aniline compounds; Antirheumatics; Benzene derivatives; Chlorinated hydrocarbons; Nonsteroidal anti-inflammatories; Phenylacetates; Pyrrolidines; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Musculoskeletal pain; Osteoarthritis

Most Recent Events

  • 16 May 2024 Preclinical development is ongoing in USA for Musculoskeletal pain and Osteoarthritis
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Osteoarthritis in USA (Topical, Spray)
  • 10 Aug 2023 Virpax pharmaceuticals files for provisional patent protection with United States Patent and Trademark Office (‘USPTO’) for NSAID Formulation and Method related to diclofenac epolamine metered dose spray film in the USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top